 |
|
|
 |
|
|
|
|
| July 31, 2001 |
|
| Mitsubishi-Tokyo and Takeda Form an Alliance
on an Anti Cardiac Disease Agent |
|
Mitsubishi-Tokyo Pharmaceuticals, Inc.
Takeda Chemical Industries, Ltd. |
|
Mitsubishi-Tokyo Pharmaceuticals, Inc. ("Mitsubishi-Tokyo," President: Ryuichi
Tomizawa) and Takeda Chemical Industries, Ltd. ("Takeda," President: Kunio Takeda)
jointly announced today that they have signed an agreement for Mitsubishi-Tokyo's
MCC-135, a novel agent for cardiac diseases. The agreement gives Takeda rights
to develop and market oral formulation of this compound for the world except a
part of Asian countries including Japan.
MCC-135 is an agent for cardiac diseases including heart failure or myocardial
infarction, which demonstrates improving effects for cardiac diastolic dysfunction
and protective effects for cardiac necrosis by enhancing Ca2+
uptake by the sarcoplasmic reticulum and inhibiting the sarcolemmal Na+/Ca2+
exchange.
In Europe and the U.S., Mitsubishi-Tokyo has been conducting phase 2 clinical
study of MCC-135 oral formulation for heart failure. Takeda will succeed Mitsubishi-Tokyo
and will conduct phase 2 clinical studies targeted for heart failure and myocardial
infarction.
Regarding the injectable formulation of MCC-135, Mitsubishi-Tokyo will develop
and market it worldwide. The company aims to maximize its global development capability
by cooperatively developing MCC-135 with Takeda, and believes that the compound
will be a crucial product to realize the corporate image as an international pharmaceutical
company.
Takeda expects that MCC-135 oral formulation will strengthen its cardiovascular
franchise, currently including anti-hypertension drug candesartan cilexetil, and
will expand its product pipeline in Europe and the U.S.
| For further information, please contact |
| Mitsubishi-Tokyo Pharmaceuticals, Inc. |
| Tel: [+81]-(0)3-6414-3730 |
| Takeda Chemical Industries, Ltd. |
| Tel: |
(Osaka) [+81] 6-6204-2060
(Tokyo) [+81] 3-3278-2039 |
|
|
|
|
 |
|
|
|
